CITN prioritizes our research by selecting novel agents with proven immunologic or physiologic function. We conduct small (early phase), novel studies of these high-priority agents in patients with cancer that would lead to larger phase trials, ultimately resulting in FDA approval.
Given our limited funding and the urgency of developing new cancer immunotherapies, CITN is strategic in our choice of agents selected for early phase testing. We prioritize agents that
CITN relies on our membership of leading cancer immunologists to access the most promising immunotherapeutic agents known to date. We then collaborate with our industry and philanthropic partners to develop early-stage trials that provide the quickest route from proof of concept to patient benefit and regulatory approval.